Related Experiment Video

Updated: Apr 3, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K

Systemic effects of treatment with mTOR inhibitors in tuberous sclerosis complex: a comprehensive review

K Sadowski1, K Kotulska1, R A Schwartz2,3

  • 1Department of Neurology and Epileptology, The Children's Memorial Health Institute, Warsaw, Poland.

Journal of the European Academy of Dermatology and Venereology : JEADV
|September 26, 2015
PubMed

Insights

mTOR inhibitors show promise for treating tuberous sclerosis complex (TSC) by targeting the overactive mTOR pathway. This review analyzes their systemic effects across various TSC manifestations.

Area of Science:

  • Genetics
  • Oncology
  • Pharmacology

Background:

  • Tuberous sclerosis complex (TSC) is a genetic disorder causing benign tumors due to mammalian target of rapamycin (mTOR) pathway overactivation.
  • mTOR inhibitors are effective for specific TSC-related tumors like subependymal giant cell astrocytomas (SEGAs) and renal angiomyolipomas (AMLs).

Purpose of the Study:

  • To systematically review clinical data on the systemic effects of mTOR inhibitors in TSC patients.
  • To evaluate the influence of mTOR inhibition on diverse TSC manifestations.

Main Methods:

  • Systematic literature review of clinical studies.
  • Analysis of data on mTOR inhibitor efficacy and systemic impact in TSC.

Main Results:

  • mTOR inhibitors demonstrate targeted efficacy against specific TSC pathologies (SEGAs, AMLs).
  • Emerging evidence suggests potential systemic, disease-modifying effects of mTOR inhibitors in TSC.

Conclusions:

  • mTOR inhibitors offer targeted treatment for certain TSC tumors.
  • Further research is warranted to confirm the systemic and disease-modifying potential of mTOR inhibitors in TSC.

More Related Videos

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

632
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

19.6K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.4K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K